Compound reference
Half-lives, regulatory status and what published trials actually administered, with a source on every claim.
Most pages about these compounds are published by companies selling them. These pages cite a source for every claim, and where no human study exists they say so rather than repeating a figure with nothing behind it.
Incretin receptor agonists
Act on the GLP-1 receptor, and in some cases on the GIP and glucagon receptors as well.
- TirzepatideTirzepatide is a dual GIP and GLP-1 receptor agonist administered as a once-weekly subcutaneous injection.
- SemaglutideSemaglutide is a GLP-1 receptor agonist available as a once-weekly subcutaneous injection and as a daily oral tablet.
- RetatrutideRetatrutide is an investigational triple agonist of the GIP, GLP-1 and glucagon receptors, studied as a once-weekly subcutaneous injection.
Growth hormone secretagogues
Prompt the pituitary to release growth hormone rather than supplying growth hormone directly.
- TesamorelinTesamorelin is a synthetic growth hormone-releasing factor analogue approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy.
- IbutamorenIbutamoren is an orally active ghrelin receptor agonist that raises growth hormone and IGF-1 levels.
- CJC-1295CJC-1295 is a long-acting analogue of growth hormone-releasing hormone, modified to bind albumin and extend its duration of action.
- IpamorelinIpamorelin is a selective growth hormone secretagogue that acts at the ghrelin receptor.
Melanocortin receptor agonists
Act on melanocortin receptors, which is why pigmentation and nausea recur across the class.
Peptides marketed for tissue repair
Grouped by the claim they are sold on rather than by chemistry. They are structurally unrelated: one is a gastric pentadecapeptide, the other a fragment of thymosin beta-4.